Estimating lead time and sensitivity in a screening program without estimating the incidence in the screened group
Related Experiment Video
Updated: Oct 11, 2026

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
Published on: January 27, 2014
H Straatman1, P G Peer, A L Verbeek
1University of Nijmegen, Department of Epidemiology, The Netherlands.
Abstract:
Early indicators of the effectiveness of a screening test for chronic diseases such as breast cancer are the length of time the diagnosis is advanced by screening, the lead time, and the sensitivity of the screening test. This paper describes a model for simultaneously estimating the mean lead time and the sensitivity when only the number of cancers detected at the successive screenings and the number of cancers occurring in the time interval between the screening examinations are known. This model is particularly useful in assessing the effect of screening when the underlying cancer incidence in the screened group is unknown. The model is fitted to the data of 235 screen-detected breast cancer cases and 146 interval cancers diagnosed across 6 screening rounds of the program in Nijmegen. The maximum likelihood estimate for the mean lead time ranges from 1.3 years in the under age 50 group to 2.2 years in the age 50-65 group, both estimates having large confidence intervals. The corresponding sensitivity estimates are 0.92 and 1.00.
More Related Videos
Related Concept Videos
Contaminants and Errors
Another key consideration is determining the appropriate number of samples required to...
Sensitivity, Specificity, and Predicted Value
Sensitivity is the...
Introduction To Survival Analysis
The primary goal of survival analysis is to estimate survival time—the time until a...
Kaplan-Meier Approach
Assumptions of Survival Analysis
Comparing the Survival Analysis of Two or More Groups

